NEW YORK, September 23, 2015 /PRNewswire/ --
ACI Association has initiated research coverage on the following
equities: Amicus Therapeutics, Inc. (NASDAQ: FOLD), Arena
Pharmaceuticals, Inc. (NASDAQ: ARNA), Cerner Corporation
(NASDAQ: CERN), Amarin Corporation PLC (NASDAQ: AMRN),
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). On Tuesday, September 22, 2015, NASDAQ ended at
4,756.72, down 1.50%, DJIA declined 1.09% to finish the day at
16,330.47, and the S&P closed at 1,942.74, down 1.23%. Register
for your complimentary reports at the links given below.
--
Amicus Therapeutics Inc.
--
Amicus Therapeutics Inc.'s stock edged lower by 4.84% to close
Tuesday's session at USD 15.33. The
company's shares oscillated between USD
14.91 and USD 15.99 in trade during the day. The stock
recorded a trading volume of 2.38 million shares, which was above
its 50-day daily average volume of 2.06 million shares and above
its 52-week average volume of 1.86 million shares. Over the last
three days Amicus Therapeutics Inc.'s shares have declined by
13.00% and in the past one week the stock has moved down 15.91%.
Furthermore, over the last three months the stock has gained 8.57%
and in the past six months the shares have picked up 39.24%. The
stock is trading at a price to book ratio of 5.52 while the
historical PB ratio is close to 6.51. Sign up and read the free
notes on FOLD at: http://www.aciassociation.com/FOLD.pdf
--
Arena Pharmaceuticals Inc.
--
The stock of Arena Pharmaceuticals Inc. remained flat to close
Tuesday's session at USD 2.61.
However, shares of the company moved in the range of USD 2.52 and USD
2.62 marking a new 52-week low during the session. A trading
volume of 2.36 million shares was recorded, which was lower than
its 150-day daily average volume of 3.22 million shares and below
its 52-week average volume of 4.52 million shares. Over the last
five days Arena Pharmaceuticals Inc.'s shares have declined by
10.00%. Additionally, in the past six months the shares have
registered a loss of 42.13%. The company has generated negative
returns of 12.12% in the past one month and 41.87% in the last
three months, on a compounded total return basis. The stock is
trading at a price to book ratio of 5.89 and price to sales ratio
of 16.30. Register for free on ACI Association and access the
latest research on ARNA at:
http://www.aciassociation.com/ARNA.pdf
--
Cerner Corp
--
Cerner Corp's stock decreased by 0.88% to close Tuesday's
session at USD 62.92. The company's
shares fluctuated in the range of USD
62.09 and USD 64.00 in trade
during the day. A total of 2.28 million shares exchanged hands,
which was lesser than its 50-day daily average volume of 2.63
million shares and was above its 52-week average volume of 1.79
million shares. Over the last three days Cerner Corp's shares have
declined by 2.48% while in the past one week the stock has moved up
0.45%. Furthermore, over the last three months the stock has lost
10.01% and in the past six months the shares have shed 14.94%.
Further, the company is trading at a price to earnings ratio of
43.69 and the stock is at a price to book ratio of 5.62. This
compares to a historical PE ratio of 43.37 and historical PB ratio
of 6.24. The complete research on CERN is available for free at:
http://www.aciassociation.com/CERN.pdf
--
AMARIN CORPORATION PLC
--
AMARIN CORPORATION PLC's stock slipped by 0.85% to close
Tuesday's session at USD 2.32. The
company's shares oscillated between USD 2.28
and USD 2.35. The stock recorded a trading volume of 2.26
million shares, which was above its 50-day daily average volume of
1.66 million shares and below its 52-week average volume of 2.70
million shares. Over the last five days AMARIN CORPORATION PLC's
shares have declined by 2.11% and in the past one month the stock
has gained a momentum of 14.29%. In addition, over the last three
months the stock has lost 9.38% while year to date the shares have
picked up 136.81%. Free in-depth research on AMRN is available at:
http://www.aciassociation.com/AMRN.pdf
--
BioMarin Pharmaceutical Inc.
--
BioMarin Pharmaceutical Inc.'s stock declined 3.37% to close
Tuesday's session at USD 117.97. The
share price vacillated between USD 117.02
and USD 121.50. The stock recorded a trading volume of 2.26
million shares, which was above its 50-day daily average volume of
1.25 million shares and above its 52-week average volume of 1.32
million shares. Over the last three days BioMarin Pharmaceutical
Inc.'s shares have declined by 10.72% and in the past one week the
stock has moved down 10.55%. Moreover, year to date the shares have
picked up 30.50%. On a compounded total return basis, the company
has returned 5.75% in the last half a year and 68.38% in the past
one year. The stock is trading at a price to book ratio of 8.06
while the historical PB ratio is close to 8.82. The complimentary
notes on BMRN can be downloaded in PDF format at:
http://www.aciassociation.com/BMRN.pdf
--
About ACI Association:
Active Charter Investors Association ("ACI Association")
produces regular sponsored and non-sponsored reports, articles,
stock market blogs, and popular investment newsletters covering
equities listed on NYSE and NASDAQ and micro-cap stocks. ACI
Association has two distinct and independent departments. One
department produces non-sponsored analyst certified content
generally in the form of press releases, articles and reports
covering equities listed on NYSE and NASDAQ and the other produces
sponsored content (in most cases not reviewed by a registered
analyst), which typically consists of compensated investment
newsletters, articles and reports covering listed stocks and
micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
ACI Association has not been compensated; directly or
indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the
"Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as
necessary, based on sound investment judgment and publicly
available information which is believed to be reliable. The
Reviewer and the Sponsor have not performed any independent
investigations or forensic audits to validate the information
herein. Unless otherwise noted, any content outside of this
document has no association with the Author, the Reviewer, or the
Sponsor (collectively referred to as the "Production Team") in any
way. The Production Team is compensated on a fixed monthly basis
and do not hold any positions of interest in any of the securities
mentioned herein.
NO WARRANTY
ACI Association, the Author, the Reviewer and the Sponsor
(collectively referred to as the "Publishers") are not responsible
for any error which may be occasioned at the time of printing of
this document or any error, mistake or shortcoming. No liability is
accepted by the Publishers whatsoever for any direct, indirect or
consequential loss arising from the use of this document. The
Publishers expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from
any reliance placed on the information in this document.
Additionally, the Publishers do not (1) guarantee the accuracy,
timeliness, completeness or correct sequencing of the information,
or (2) warrant any results from use of the information. The
included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither ACI Association nor any party affiliated
with us is a registered investment adviser or broker-dealer with
any agency or in any jurisdiction whatsoever. To download our
report(s), read our disclosures, or for more information, visit
http://www.aciassociation.com/.
RESTRICTIONS
ACI Association is not available to residents of Belarus, Cuba, Canada,
Iran, North Korea, Sudan, Syria
or Somalia.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE www.aciassociation.com